Lysergic Acid Diethylamide
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT07017478 | Jun 2025 → Jun 2026 | major depressive disorder | University of Chicago | Completed | No outcome recorded |
| Phase 0 | NCT05953038 | Nov 2023 → Dec 2027 expected | — | Rigshospitalet, Denmark | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02308969 | Dec 2014 → Sep 2015 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 19 trials | ||||||
| Phase 1 | NCT07503002 | Oct 2026 → Jul 2027 expected | major depressive disorder | Johns Hopkins University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06899334 | Apr 2025 → Aug 2026 overdue | — | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
| Phase 1 | NCT04516902 | Jan 2021 → Aug 2022 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT04558294 | Oct 2020 → Aug 2021 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT04227756 | May 2020 → Sep 2022 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT03934710 | Apr 2019 → Jun 2021 | — | University of Chicago | Completed | No outcome recorded |
| Phase 1 | NCT03790358 | May 2018 → Jan 2023 | — | University of Chicago | Completed | No outcome recorded |
| Phase 1 | NCT05674669 | Oct 2015 → Jul 2016 | — | Eleusis Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04421105 | Jun → Oct 2015 | — | Eleusis Therapeutics | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT05883540 | Jun 2024 → Sep 2027 expected | anxiety, depressive disorder | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
| Phase 2 | NCT03781128 | Jan 2019 → Dec 2025 overdue | cluster headache syndrome | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
| Phase 2 | NCT03153579 | Jun 2017 → Dec 2021 | anxiety disorder | University Hospital, Basel, Switzerland | Completed | Met primary |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT05175430 Comparator | Oct 2022 → Feb 2024 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT05177419 Comparator | May 2022 → Mar 2025 | — | University of Fribourg | Completed | No outcome recorded |
| Phase 2 | NCT05474989 Comparator | Jan 2026 → Oct 2028 expected | alcohol-related disorders | Felix Mueller | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lysergic Acid Diethylamide | “Here, we are examining the effects of four repeated low doses of lysergic acid diethylamide (LSD), compared to placebo, administered to healthy adults at 3-4 day intervals, on...” NCT03934710 ↗17“This study aimed to investigate the efficacy and safety of lysergic acid diethylamide (LSD)-assisted therapy in patients who experienced anxiety with or without association...” PMID 36266118 ↗ Sep 2022 “The purpose of this study is to determine the safety and clinical effectiveness of a shortened lysergic acid diethylamide (LSD) experience.” NCT07503002 ↗ “Lysergic acid diethylamide (LSD), psilocybin, and N,N-dimethyltryptamine (DMT) are serotonergic hallucinogens (psychedelics)” NCT06899334 ↗ “Lysergic acid diethylamide (LSD) was investigated in numerous clinical trials during the 1950s and 1960s.” NCT05474989 ↗ “Mescaline, lysergic acid diethylamide (LSD), and psilocybin are classic serotonergic psychedelics.” PMID 37231080 ↗ May 2023 “one promising example of these compounds is lysergic acid diethylamide (LSD)” NCT07017478 ↗ “Lysergic Acid Diethylamide” NCT02308969 ↗ |
| Known as | D-Lysergic Acid Diethylamide | “D-Lysergic Acid Diethylamide (LSD) D-tartrate as oral drinking solution (water / ethanol 20% m/m)” NCT05953038 ↗ |
| Known as | LSD | “The purpose of this study is to determine the safety and clinical effectiveness of a shortened lysergic acid diethylamide (LSD) experience.” NCT07503002 ↗10“Lysergic Acid Diethylamide (LSD) 50µg” NCT05674669 ↗ “Lysergic acid diethylamide (LSD) 5µg” NCT04421105 ↗ “lysergic acid diethylamide (LSD)” NCT03781128 ↗ “LSD 0.1 mg per os, single dose” NCT04227756 ↗ “LSD” NCT05177419 ↗ |
| Action | Activate | “5-hydroxytryptamine (HT)2A receptor agonist” NCT02308969 ↗ |
| Modality | Other / unclassified | “LSD is a so-called "classic" or serotonergic hallucinogen or psychedelic.” NCT04516902 ↗ |
| Route | Oral | “100ug per os, single dose” NCT02308969 ↗ |